Pharmaceuticals News and Research

RSS

Moxidectin being tested for onchocerciasis

A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.

1 Jul 2009

Hospira receives FDA approval for Azithromycin for injection

Hospira, Inc has announced it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage System.

30 Jun 2009

Drug companies increasingly use medical science liaisons

The Wall Street Journal reports that drug companies are increasingly using medical science liaisons: "Pharmaceutical companies are barred by the Food and Drug Administration from promoting unapproved drug uses, called off-label use, but they are using employees called 'medical science liaisons,' who are often physicians and pharmacists, as a legal way to discuss those uses.

29 Jun 2009

Heart attacks kill 10,000 Australians each year and many could be avoided

A new report by Access Economics has revealed that this year 80,000 Australians can expect to be treated in hospital for heart attacks or chest pain - at a cost to the economy of $18 billion and 10,000 people will die from a heart attack.

28 Jun 2009

Sources: Hospitals may strike deal to save $200 billion

Hospitals could sign on to an agreement with Senate health reform leader Max Baucus, D-Mont., and the White House to help save up to $200 billion as part of the overhaul plan, lobbyist and health industry sources tell Roll Call.

25 Jun 2009

Scientists investigate health benefits of molecule associated with male sexual arousal

Medical scientists at the University of Leicester are investigating how signalling molecules known to control blood pressure and penile erection act to regulate brain function and which have potential for treatments of migraine, chronic pain, epilepsy and Alzheimer's disease.

24 Jun 2009

Innovative Virtual Patient system for allergy sufferers

Keele University has developed a new programme to be used with its innovative Virtual Patient system to help pharmacists train in dispensing medication and providing advice on the treatment of hay fever and allergies.

24 Jun 2009

FDA approves generic emergency contraceptive Plan B (levonorgestrel) tablets

The U.S. Food and Drug Administration today approved the first generic version of the emergency contraceptive Plan B (levonorgestrel) tablets, 0.75 mg. The generic product will be available by prescription only for women ages 17 and under.

24 Jun 2009

Good bet in market pullback: health-care shares

"As sentiment and the stock market increasingly look bearish, look for the recent outperformance in health care to continue," The Wall Street Journal reports.

23 Jun 2009

Details remain unclear on Medicare drug deal

The White House formally announced the drug manufacturers' plan to lower Medicare drug prices Monday. While details still remain unclear, it appears drug companies may benefit from the deal.

23 Jun 2009

Merck partners with non-profit for neglected diseases initiative

The pharmaceutical company, Merck, announced Monday it was partnering with the non-profit Drugs for Neglected Diseases initiative (DNDi) in an effort to improve treatments for neglected tropical diseases (NTD), the AP/CNBC reports.

23 Jun 2009

Scientists block Ebola infection in cell-culture experiments - could lead to first therapy

Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells.

23 Jun 2009

Diet and exercise to alleviate treatments for prostate cancer

A DVD, developed by academics at the University of Hertfordshire, which illustrates the positive effects of diet and exercise in the treatment of prostate cancer, will be launched tomorrow.

23 Jun 2009

Scientists develop microfabricated device to measure cellular forces during tissue development

A University of Pennsylvania-led collaboration of bioengineers studying the physical forces generated by individual cells has created a tiny micron-sized device that allows researchers to measure and manipulate cellular forces as assemblies of living cells reorganize themselves into tissues.

23 Jun 2009

Obama, AARP announce agreement to cut prescription drug costs

On Monday, President Barack Obama joined with AARP chief Barry Rand to announce "an agreement among pharmaceutical companies to cut prescription drug costs for seniors - and inject some energy into his efforts at comprehensive health care reform," Politico reports. Obama said the companies' goal is to "to reduce the punishing inflation in health care while improving patient care."

22 Jun 2009

Cerebrospinal fluid shows Alzheimer's disease deterioration much earlier

It is possible to determine which patients run a high risk of developing Alzheimer's disease and the dementia associated with it, even in patients with minimal memory impairment. This has been shown by recent research at the Sahlgrenska Academy, University of Gothenburg, Sweden.

22 Jun 2009

PEPFAR and IDUs; economic crisis and health; human-rights and pharmaceutical companies

Although PEPFAR has helped to provide "antiretroviral therapy to 2.1 million people with HIV, almost all of whom live in sub-Saharan Africa, and has spent more than US$18 billion on the continent" it has failed to reach "thousands of injecting drug users in PEPFAR countries in Africa, many of whom have HIV," according to the authors of a recent comment in the journal Lancet.

21 Jun 2009

Tibotec, TB Alliance join to expedite development of promising tuberculosis drug

The pharmaceutical company Tibotec said it will join with the non-profit Global Alliance for Tuberculosis Development (TB Alliance) to speed up the development of the experimental TB drug TMC207, Health-e/IOL reports (Thom, Health-e/IOL, 6/18). Tibotec, which is a subsidiary of Johnson & Johnson, announced the news on Wednesday at the Pacific Health Summit in Seattle (Doughton, Seattle Times, 6/18).

18 Jun 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

The Federal Government should have limited, but crucial, role in comparative effectiveness

Federal officials are expected to offer recommendations this month on one of the first installments of health reform - a new initiative to compare the value and merits of competing medical treatments.

18 Jun 2009